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Vascular calcification in 
chronic kidney disease: New 
developments in drug therapy
S Huybers1 and RJM Bindels1
Controlling the development of vascular calcification in chronic 
kidney disease is essential, because it is associated with increased 
cardiovascular pathology. However, the precise mechanism of vascular 
calcification has not been completely elucidated. In the literature, 
the involvement of passive calcium and phosphate deposition as 
well as an active process stimulating the transformation of vascular 
smooth muscle cells into an osteoblastic phenotype is suggested. New 
promising insights into the etiology could lead to better treatment 
strategies, as Mizobuchi et al. now report.
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An increasing number of people, more 
than 2 in 1,000 in the United States, are 
faced with a slowly progressive loss of 
renal function, known as chronic kid-
ney disease (CKD), of which diabetes 
and hypertension are the most common 
causes. Because of a reduced glomerular 
ﬁltration rate, CKD patients excrete less 
phosphate via the urine, consequently 
developing severe hyperphosphatemia. 
Furthermore,  CKD is  l inked to 
hypocalcemia as a result of impaired 
synthesis of renal 1,25-dihydroxyvita-
min D3, the active metabolite of vitamin 
D in the body. The low serum calcium 
concentration is sensed by calcium-sens-
ing receptors in the parathyroid gland, 
which trigger the excessive secretion of 
parathyroid hormone, resulting in sec-
ondary hyperthyroidism (SHPT). Vita-
min D administration is the primary 
treatment in CKD to overcome the 
SHPT and simultaneously diminish the 
detrimental eﬀects of increased parathy-
roid hormone levels on bone. However, 
long-term vitamin D treatment has the 
potential risk of aggravating hyperphos-
phatemia and inducing severe hypercal-
cemia as overcompensation for the initial 
low calcium levels. These disturbances in 
calcium and phosphate homeostasis are 
postulated to play an important role in 
the pathogenesis of vascular calciﬁcation 
(VC). Indeed, VC is frequently observed 
in CKD and is associated with increased 
morbidity and mortality from cardio-
vascular events. Therefore, controlling 
the process of VC is an essential aspect 
of CKD treatment. To date, new factors 
stimulating VC are being recognized, 
which motivates researchers to further 
unravel the exact mechanisms involved.
Previously, it was postulated that VC 
in CKD was caused merely by a pas-
sive deposition of calcium × phosphate 
(Ca × P) products in the vascular sys-
tem, which were generated because of 
hyperphosphatemia and hypercalcemia. 
Indeed, many studies in both animals 
and humans have shown a strong positive 
correlation between hyperphosphatemia, 
hypercalcemia, and VC.1,2 Furthermore, 
in vitro studies exposing vascular smooth 
muscle cells (VSMCs) to high phosphate 
and calcium concentrations showed a 
dose-dependent increase in mineraliza-
tion.3,4 However, several recent studies 
described phenotypic changes of VSMCs 
in the vessel wall of uremic animals, 
indicating the involvement of a more 
complex mechanism. In fact, a number 
of proteins were present in elevated 
amounts in the calciﬁed vessel and were 
likely to be involved in promoting diﬀer-
entiation of VSMCs into an osteoblastic 
phenotype.1 This modiﬁcation is driven 
by the upregulation of certain transcrip-
tion factors, including core-binding fac-
tor 1α (cbfa1), also known as Runx2, and 
bone morphogenetic protein-2 (bmp-2), 
which are key regulators of VSMC dif-
ferentiation by controlling the expres-
sion of a number of osteogenic proteins, 
such as osteocalcin, osteonectin, alkaline 
phosphatase, and collagen-1 (Figure 1). 
This hypothesis was conﬁrmed in studies 
that exposed VSMCs to high phosphate 
and calcium concentrations and showed 
upregulation of cbfa1 and increased 
alkaline phosphatase production.3,5 Fur-
thermore, these osteoblastic markers are 
found to be elevated in the vasculature of 
both uremic rats and CKD patients.1,2 In 
addition, another predominant mecha-
nism by which VC occurs is through the 
loss of inhibitors. Several protective fac-
tors produced by endothelial cells were 
recognized that are able to prevent soft 
tissue calciﬁcations under normal con-
ditions. Important protectors include 
matrix Gla-protein, osteopontin, fetuin, 
and osteoprotegerin, which inhibit diﬀer-
ent pathways involved in the pathogen-
esis of VC. Ultimately, a disproportion 
in the production of both VC-promoting 
and VC-inhibiting factors could shift the 
VSMCs toward an osteoblast-like pheno-
type. The crucial question remains: what 
triggers this imbalance?
Contribution of high phosphate levels 
to VSMC diﬀerentiation is thought to be 
driven by the upregulation of a type III 
sodium-dependent cotransporter, 
called Pit-I, stimulation of which can 
subsequently upregulate cbfa1 expres-
sion.3,5,6 Additionally, proinﬂammatory 
cytokines have been postulated to reduce 
the ability of endothelial cells to produce 
certain inhibitory factors, subsequently 
1Department of Physiology, Nijmegen Centre 
for Molecular Life Sciences, Radboud University 
Nijmegen Medical Centre, Nijmegen,  
The Netherlands
Correspondence: RJM Bindels, Radboud 
University Nijmegen Medical Centre, Physiology 
(286), P.O. Box g101, 6500 H.B. Nijmegen,  
The Netherlands.  
E-mail: r.bindels@ncmls.ru.nl
see original article on page 709
664   Kidney International (2007) 72
commentar y
accelerating the VC process. However, 
further research will be required in this 
area to provide detailed evidence for the 
hypothesized pathways involved in VC 
as mentioned above.
Interestingly, vitamin D receptor 
(VDR) activation also displays eﬀects 
on vascular mineralization. It is gener-
ally known that the calciotropic hormone 
vitamin D is the key regulator involved 
in calcium homeostasis by controlling 
intestinal calcium absorption and renal 
calcium reabsorption via VDR activation. 
VDRs are distributed in a large variety of 
tissues such as VSMCs, and it is therefore 
likely that vitamin D exerts many diverse 
eﬀects throughout the body. For example, 
VDR activation plays an important role 
in regulating the inﬂammatory process 
critical in the pathogenesis of athero-
sclerosis. The atherosclerotic develop-
ment is promoted by the T-helper 1 
cells interleukin-1b, interleukin-6, and 
tumor necrosis factor and inhibited by 
T-helper 2 cells, mainly interleukin-4 
and interleukin-10. It is known that 
low VDR activation, due to untreated 
vitamin D deﬁciency in CKD, reduces 
the protective T-helper 2 cells, thereby 
promoting atherosclerotic lesions. Fur-
thermore, some studies suggest that low 
VDR activity decreases the production 
of other VC-inhibiting factors, such as 
the parathyroid hormone-related pep-
tide (PTH-rP). On the other hand, high 
VDR activity due to vitamin D supple-
mentation can exert severe hyperphos-
phatemic and hypercalcemic features. 
High phosphate and calcium levels are 
involved in enhanced passive Ca × P pre-
cipitation and the promotion of VSMC 
transformation, which both aggravate 
VC. Taken together, these data indicate 
that the involvement of vitamin D in the 
pathogenesis of VC is a biphasic process; 
both vitamin D deﬁciency and vitamin D 
excess can enhance VC. Consequently, 
controlling vitamin D levels is important 
in maintaining a healthy vessel wall.
Treatment with 1,25-dihydroxyvita-
min D3 (1,25(OH)2D3) and other VDR 
agonists, however, remains essential in 
CKD, reducing SHPT and preventing 
excessive bone resorption. More impor-
tantly, vitamin D or vitamin D agonist 
administration exerts a clear survival 
benefit in CKD patients. The use of 
1,25(OH)2D3 in end-stage renal disease 
patients was associated with a 70% lower 
risk of death from cardiovascular disease 
in comparison with a group of untreated 
patients.7 One explanation for this ben-
eﬁcial eﬀect could be that 1,25(OH)2D3 
protects VSMCs from calcification 
by suppressing cbfa1 and bmp-2 syn-
thesis.8,9 Consequently, vitamin D or 
VDR agonist supplementation remains 
extremely important, although the risk 
of highly elevated serum calcium and 
phosphate levels can clearly accelerate 
the VC process. Therefore, it is crucial 
to develop drugs that can suﬃciently 
reduce SHPT but have less hypercal-
cemic and hyperphosphatemic activity.
This topic was successfully addressed 
by Mizobuchi et al.10 (this issue), who 
investigated the eﬀects of supplement-
ing various VDR agonists, including 
doxercalciferol and paricalcitol, on 
VC. They showed that doxercalciferol 
was less hypercalcemic and hyperphos-
phatemic than 1,25(OH)2D3, but it still 
induced mineralization and increased 
the osteogenic markers cbfa1 and 
osteocalcin in the vasculature. Interest-
ingly, they observed that in uremic rats 
paricalcitol did not exert hypercalcemic 
and hyperphosphatemic eﬀects result-
ing in reduced Ca × P products and 
diminished mineralization of the vas-
culature. Besides, paricalcitol had no 
stimulatory eﬀect on cbfa1 and osteo-
calcin expression.10 Highly essential 
for CKD treatment is the fact that pari-
calcitol maintained the ability to eﬃ-
ciently reduce the SHPT. Although the 
exact mechanism of diﬀerential eﬀects 
between doxercalciferol and paricalcitol 
is unknown, it can be concluded from 
this study that paricalcitol is favorable 
over doxercalciferol in CKD therapy. 
These results are further supported 
by a study in which dialysis patients 
were treated with either calcitriol or 
paricalcitol. The paricalcitol-treated 
group showed not only a signiﬁcantly 
improved survival benefit, indicated 
by a 16% reduced mortality rate,11 but 
also a reduced number of hospitaliza-
tions and reduced hospitalization time 
as well.12 Likewise, Tentori et al.13 
reported a higher mortality for patients 
on 1,25(OH)2D3 treatment as compared 
with paricalcitol and doxercalciferol, 
although the eﬀect was small. In contrast 
to the ﬁndings described by Mizobuchi 
et al.,10 the mortality rates were similar 
for paricalcitol versus doxercalciferol.13
Figure 1 | The process of vascular calcification. Vascular calcification in chronic kidney disease 
(CKD) is induced via both passive Ca × P deposition and active transformation of vascular smooth 
muscle cells (VSMCs) into an osteoblast-like phenotype. The vitamin D receptor (VDR) agonist 
paricalcitol is very useful in the treatment of CKD patients. Besides effectively suppressing 
secondary hyperthyroidism, paricalcitol is less phosphatemic and calcemic, therefore decreasing 
the risk for vascular calcification.
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In conclusion, we can learn from these 
new studies that the control of plasma 
calcium and phosphate in CKD patients 
is important in prevention of VC. New 
information about the precise regulators 
of VSMC diﬀerentiation into osteoblastic 
cells is rapidly increasing. Future studies 
should now focus on unraveling the VC 
pathways in detail and investigating the 
exact diﬀerences among the diverse vita-
min D agonists in order to develop new 
drugs that can speciﬁcally treat SHPT 
without inducing VC.
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Hemodialysis vascular access: The 
Achilles’ heel remains
SJ Schwab1
Maintaining vascular access for hemodialysis remains a leading cause 
of patient morbidity. Surveillance and other technologies continue 
to improve, but the goal of dramatically improved AV access patency 
remains elusive.
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Maintenance of access to the circulation 
for hemodialysis continues to be the Achil-
les’ heel of dialysis therapy. This access to 
the circulation is best accomplished by 
the use of arteriovenous (AV) access com-
posed of native AV ﬁstulae and synthetic 
AV ﬁstulae (AV grafts).1–3
Much work in this area has been accom-
plished in the past 20 years. Investigators 
have determined that endothelial and 
fibromuscular hyperplasia of the vein, 
leading to lumen shrinkage or stenosis, is 
the leading cause of failure of mature AV 
access.1–3 These areas of stenosis occur 
predominantly in the area of the vein-
graft anastomosis in AV grafts and areas of 
turbulence or previous cannulation in AV 
access proximal outﬂow veins of AV ﬁs-
tulae and AV grafts (Figure 1). It has been 
established that these stenoses lead to ﬂow 
stasis, thrombosis, and ultimately, if uncor-
rected, AV access abandonment. Conse-
quently, survival of AV access in general 
and AV grafts in particular continues to 
be less than 50% at 3 years of use.1–3 The 
original Kidney Disease Outcomes Quality 
Initiative (KDOQI) panel determined that 
delaying correction of stenoses until after 
thrombosis results in tight stenoses that 
are diﬃcult to correct by either percutane-
ous methods or surgical revision. Taking a 
page from the treatment of coronary artery 
disease, it was reasoned that AV access 
survival would be improved by applica-
tion of prospective surveillance techniques 
followed by early preemptive therapy. The 
published evidence supported this treat-
ment strategy. This strategy (based on the 
sum of the published evidence) continues 
to be the recommendation of the most 
recent KDOQI panel.1 Several trials, how-
ever, have emerged to challenge aspects of 
this theory.
Wijnen and co-investigators from Maas-
tricht, The Netherlands4 (this issue), have 
now advanced another sophisticated AV 
access surveillance technique. Surveil-
lance techniques have evolved from the 
initial description of dynamic venous 
pressure through techniques for measur-
ing static venous pressure to techniques 
for the quantitation of access blood ﬂow.1 
Access blood ﬂow measurements deter-
mined initially by external Doppler ultra-
sound developed as the most sensitive, 
and speciﬁc, but costly of the surveillance 
techniques for the detection of AV access 
stenoses.1 Less expensive AV access ﬂow 
measurements using ultrasound dilu-
tion and other techniques subsequently 
emerged as preferred because of equal 
accuracy, decreased expense, and ease of 
use. Wijnen et al.4 describe a potential 
advance in AV access ﬂow measurement 
techniques. It is clear that our ability to 
detect stenoses is improving with every 
newly described technique. Detection of 
hemodynamically significant stenoses, 
however, is only the ﬁrst step in improv-
ing vascular access patency. The larger 
challenge is in developing a mechanism 
